It’s a small, spring-like device that props the sinus open after surgery. Keeping the sinus open has been proven to help enhance healing and prevent scarring. PROPEL® contains an advanced, anti-inflammatory medicine that it delivers directly into the tissues that need it. This reduces inflammation, which aids in healing. After about 30 to 45 days, PROPEL dissolves, leaving the sinus healed and open.
After opening the sinus in surgery, the ENT places PROPEL inside of it. Because PROPEL has a spring-like design, it stays in place. It then delivers a powerful medication to reduce inflammation and promote healing. PROPEL delivers the medication in a slow, sustained manner directly to the area that needs it. PROPEL typically dissolves over 30 to 45 days.
Someone considering sinus surgery for chronic sinusitis in the ethmoid sinuses — including someone who has had sinus surgery in the past but needs it again — may be an appropriate candidate for the benefits of PROPEL and should consult with their doctor about it. PROPEL is not for everyone, for example, people who are allergic to the drug, mometasone furoate, or to certain polymers are not candidates for PROPEL. Additional information on risks associated with PROPEL is available here: IntersectENT.com.
PROPEL dissolves over 30 to 45 days following the surgery. During that time, PROPEL is designed to hold the sinus open, delivering medication directly where it is needed, and slowly dissolves. There is no need to remove it. Clinical studies have shown that patients show symptom improvements even six months following the surgery.1
1. National Health Interview Survey 2012
The purpose of the site is to help create awareness about sinusitis and treatment options for the disease. Please note that information contained on this site is not medical advice. It should not be used as a substitute for speaking with your physician. Always talk with your physician about diagnosis and treatment information.
The PROPEL sinus implants are intended for use after sinus surgery to maintain patency and to locally deliver steroids to the sinus mucosa: PROPEL for use in the ethmoid sinus, PROPEL Mini for use in the ethmoid sinus and frontal sinus opening, and PROPEL Contour for use in the frontal and maxillary sinus ostia. The implants are intended for use in patients ≥18 years of age. Contraindications include patients with intolerance to mometasone furoate (MF) or a hypersensitivity to bioabsorbable polymers. Safety and effectiveness of the implants in pregnant or nursing females have not been studied. Risks may include, but are not limited to, pain/pressure, displacement of implant, possible side effects of intranasal MF, sinusitis, epistaxis, and infection. For complete prescribing information see IFU at www.IntersectENT.com. Rx only.